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2009 Virus by Blood 
Transfusion
To the Editor: Inﬂ  uenza A pan-
demic (H1N1) 2009 virus emerged in 
early 2009 in Mexico and has since 
spread worldwide. In Japan, the ﬁ  rst 
outbreak of the novel inﬂ  uenza was 
reported in May 2009 (1) and became 
pandemic in November. Although no 
cases of transfusion-transmitted inﬂ  u-
enza have been published, evidence 
exists of brief viremia before onset 
of symptoms (2,3). The possibility 
of transmission of this virus through 
transfusion of donated blood is of con-
cern. The Japanese Red Cross Blood 
Centers have intercepted blood prod-
ucts with accompanying postdonation 
information indicating possible pan-
demic (H1N1) 2009 infection and at-
tempted to identify the viral genome 
in those products by using nucleic acid 
ampliﬁ  cation technology (NAT).
During June–November 2009, 
blood samples were collected from 
plasma and erythrocyte products that 
had been processed from donations; 
postdonation information indicated 
diagnosis of pandemic (H1N1) 2009 
infection soon after donation. Viral 
RNA was extracted from plasma sam-
ples and erythrocyte fractions by using 
a QIAamp Virus Biorobot MDx kit 
(QIAGEN, Valencia, CA, USA) and 
a High Pure Viral Nucleic Acid Large 
Volume kit (Roche Diagnostics, India-
napolis, IN, USA), respectively. RNA 
samples were subjected to real-time 
reverse transcription–PCR (RT-PCR) 
of hemagglutinin (HA) and matrix (M) 
genes of inﬂ  uenza A by using PRISM 
7900 (Applied Biosystems, Foster 
City, CA, USA). The RT-PCR of HA 
was speciﬁ   c for pandemic (H1N1) 
2009 virus, whereas the RT-PCR of M 
was designed to detect both pandemic 
(H1N1) 2009 and seasonal inﬂ  uenza 
A viruses. The sequences of probes 
and primers were synthesized accord-
ing to the protocols developed by the 
Japanese National Institute of Infec-
tious Diseases (4). Either 200 μL of 
a plasma sample or 100 μL of packed 
erythrocytes was used for each test, 
and the test was performed 2× for each 
gene in each sample. Before the inves-
tigation using donated blood samples, 
the sensitivity of the NAT system was 
checked by spiking experiments. Viral 
particles of pandemic (H1N1) 2009 
virus (A/California/04/2009 [H1N1]), 
donated by the National Institute of 
Infectious Diseases, were spiked into 
plasma and erythrocyte samples from 
healthy volunteers. Viral RNA was 
detected in the plasma samples spiked 
with viral particles corresponding to 
300 genome equivalents/mL and in 
the packed erythrocyte samples spiked 
with viral particles corresponding to 
3,000 genome equivalents/mL.
NAT was conducted by using 96 
plasma and 67 erythrocyte samples ob-
tained from 96 blood donors who had 
symptoms of inﬂ  uenza within 7 days 
postdonation. For 20 donors, pandem-
ic (H1N1) 2009 was diagnosed within 
1 day postdonation and, for another 
20, within 2 days postdonation (Fig-
ure). Pandemic (H1N1) 2009 virus 
was not found in any of the samples 
tested, but it was consistently detected 
in the external positive control. These 
results suggest that the viremia with 
pandemic (H1N1) 2009 virus, if any, 
is very low and can be missed by cur-
rent NAT or that the viremic period is 
too brief to identify viremia. Although 
the risk for transmission of pandemic 
inﬂ  uenza by transfusion seems to be 
low, further investigation is needed to 
elucidate this risk.
Chieko Matsumoto, 
Rieko Sobata, 
Shigeharu Uchida, 
Takao Hidaka, Syunya Momose, 
Satoru Hino, Masahiro Satake, 
and Kenji Tadokoro
722  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 4, April 2010
Figure. Number of blood donations from persons for whom pandemic (H1N1) 2009 infection 
was diagnosed postdonation and time between donation and diagnosis, by donor age, 
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Rapid Emergence 
of Oseltamivir 
Resistance
To the Editor: The inﬂ  uenza 
A pandemic (H1N1) 2009 virus has 
spread globally since it ﬁ  rst appeared 
in Mexico in April 2009. This third 
inﬂ   uenza pandemic since the Span-
ish inﬂ   uenza pandemic of 1918 (1) 
has caused at least 400,000 infections 
within 6 months; estimated mortality 
rate is 1.2% (2). Emergence of osel-
tamivir resistance in the pandemic 
(H1N1) 2009 virus is a rising chal-
lenge to global control of the pan-
demic. So far, 39 oseltamivir-resistant 
pandemic (H1N1) 2009 viruses have 
been reported worldwide (3). Among 
the 32 resistant strains reported in Oc-
tober 2009, a total of 13 (41%) were 
associated with postexposure chemo-
prophylaxis and 16 (50%) were from 
samples of patients receiving oselta-
mivir (3). We report rapid emergence 
of resistance (H275Y mutation) in a 
patient, 4 days after early treatment 
with standard doses of oseltamivir for 
pandemic (H1N1) 2009 pneumonia.
On September 1, 2009, a 20-year-
old man with mental retardation con-
sulted the emergency department of 
Kaohsiung Veterans General Hospital 
after 1 day of fever, sore throat, and 
nonproductive cough. A rapid diag-
nostic antigen test (Quick Vue Inﬂ  uen-
za test; Quidel, San Diego, CA, USA) 
showed the man to be positive for 
inﬂ  uenza A. He was hospitalized for 
bilateral pneumonitis and treated with 
oseltamivir (75 mg 2×/day for 5 days), 
ampicillin/sulbactam, and erythromy-
cin. However, a progressive increase 
in bilateral perihilar interstitial in-
ﬁ  ltration developed on the third day, 
accompanied by increasing dyspnea. 
Inﬂ  uenza A pandemic (H1N1) 2009 vi-
rus was isolated from the patient’s na-
sopharyngeal secretions on days 1 and 
4 by using MDCK cells. After DNA 
sequence analysis of the neuramini-
dase gene, the mutation of H275Y was 
not found in the ﬁ  rst isolate, but se-
quence analysis of the second isolate 
detected mixed populations (C/T) in 
the 823-nt position of the neuramini-
dase gene. Only a single pattern (T) 
was found from the cultured viruses, 
indicating a mixed quasispecies of 
oseltamivir-resistant and -susceptible 
viruses emerging after 4 days of os-
eltamivir treatment. The oseltamivir-
resistant viruses become dominant in 
the cell culture–propagated viruses. 
Chan et al. reported a similar case in 
which the original clinical specimens 
contained a mixed population of vari-
ants, and oseltamivir-resistant viruses 
become dominant after the passage in 
MDCK cells (4).
On his 9th day in the hospital, the 
patient was intubated because of acute 
respiratory distress syndrome (Figure) 
and given levoﬂ  oxacin. Urine samples 
were negative for Pneumococcus and 
Legionella spp. antigens. The patient 
improved and was extubated on hos-
pital day 16.
Paired serologic test results were 
negative for Mycoplasma pneumoniae 
and Legionella spp. antibody; howev-
er, immunoglobulin G for Chlamydia 
pneumoniae increased 4-fold. By 37 
days after illness onset, clinical signs 
and symptoms resolved and bilateral 
lineoreticular inﬁ  ltration was reduced.
On August 8, 2009, Taiwan had 
the most devastating typhoon (Ty-
phoon Morakot) in 50 years. The 
patient reported here had stayed in a 
typhoon evacuation camp for 1 week 
before his inﬂ  uenza signs and symp-
toms developed. Although 4 sporadic 
cases of pandemic (H1N1) 2009 in-
fections were reported from the same 
camp, none of the isolated viruses 
harbored the H275Y mutation in the 
neuraminidase gene. No evidence of 
virus transmission was found among 
healthcare personnel, family members, 
and camp members who had been in 
close contact with the patient.
Oseltamivir has been recommend-
ed by the US Centers for Disease Con-
trol and Prevention for the treatment of 
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as well as letters reporting cases, 
outbreaks, or original research are 
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contain material not previously pub-
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